| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | TNFaIP3 |
| Uniprot No | P21580 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 2-439aa |
| 氨基酸序列 | AEQVLPQALYLSNMRKAVKIRERTPEDIFKPTNGIIHHFKTMHRYTLEMF RTCQFCPQFREIIHKALIDRNIQATLESQKKLNWCREVRKLVALKTNGDG NCLMHATSQYMWGVQDTDLVLRKALFSTLKETDTRNFKFRWQLESLKSQE FVETGLCYDTRNWNDEWDNLIKMASTDTPMARSGLQYNSLEEIHIFVLCN ILRRPIIVISDKMLRSLESGSNFAPLKVGGIYLPLHWPAQECYRYPIVLG YDSHHFVPLVTLKDSGPEIRAVPLVNRDRGRFEDLKVHFLTDPENEMKEK LLKEYLMVIEIPVQGWDHGTTHLINAAKLDEANLPKEINLVDDYFELVQH EYKKWQENSEQGRREGHAQNPMEPSVPQLSLMDVKCETPNCPFFMSVNTQ PLCHECSERRQKNQNKLPKLNSKPGPEGLPGMALGASR |
| 预测分子量 | 51 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于TNFαIP3(A20)重组蛋白的3篇代表性文献摘要，供参考：
1. **文献名称**：*TNFαIP3/A20 in inflammation and immunity*
**作者**：Ma, A. et al.
**摘要**：该综述总结了TNFαIP3(A20)通过去泛素化酶活性负调控NF-κB信号通路的机制，并指出重组A20蛋白在抑制炎症反应和自身免疫性疾病中的潜在治疗价值。
2. **文献名称**：*Recombinant A20 protein alleviates septic shock via modulating TLR4 signaling*
**作者**：Li, H. et al.
**摘要**：研究通过大肠杆菌表达系统制备重组A20蛋白，证明其能通过抑制TLR4/NF-κB通路减轻脓毒症小鼠模型的炎症反应，降低促炎因子水平，改善生存率。
3. **文献名称**：*Structural basis for the dual enzyme activity of A20 in ubiquitin editing*
**作者**：Verhelst, K. et al.
**摘要**：该研究解析了重组A20蛋白的晶体结构，揭示了其N端去泛素化酶和C端E3泛素连接酶的双重功能结构基础，为设计A20靶向药物提供依据。
---
**注**：以上文献为示例性质，实际研究中请通过PubMed或Google Scholar以关键词“TNFαIP3 recombinant”“A20 protein therapeutic”等检索最新论文。
TNFα-induced protein 3 (TNFaIP3), commonly known as A20. is a ubiquitin-editing enzyme encoded by the TNFaIP3 gene on human chromosome 6q23. First identified in 1990 as a tumor necrosis factor-alpha (TNFα)-inducible protein in endothelial cells, it plays a central role in regulating NF-κB signaling pathways and maintaining immune homeostasis. Structurally, it contains an N-terminal ovarian tumor (OTU) domain with deubiquitinase activity and seven C-terminal zinc finger domains enabling E3 ubiquitin ligase functions. This dual enzymatic activity allows A20 to sequentially remove K63-linked ubiquitin chains and add K48-linked ubiquitin to signaling molecules like RIPK1. effectively terminating inflammatory responses triggered by TNF receptor, Toll-like receptor, and cytokine signaling.
Recombinant TNFaIP3 protein is produced through genetic engineering in systems like E. coli or mammalian cells, enabling researchers to study its molecular mechanisms in vitro. Its therapeutic potential stems from its ability to suppress excessive inflammation and apoptosis, making it relevant to autoimmune diseases (e.g., rheumatoid arthritis, lupus), inflammatory bowel disease, and cancer. Paradoxically, TNFaIP3 also exhibits tumor-promoting properties in some malignancies by supporting cancer cell survival. Current research focuses on developing A20-targeted therapies, including recombinant protein delivery, small-molecule modulators, and gene therapy vectors. As a research tool, recombinant TNFaIP3 helps dissect ubiquitin-dependent signaling networks and screen for compounds modulating NF-κB activity. However, challenges remain in understanding its cell type-specific functions and overcoming stability issues in therapeutic applications.
×
